Author information
Abstract
BACKGROUND AND PURPOSE:
Cannabis or cannabinoids produce characteristic tetrad effects – analgesia, hypothermia, catalepsy, and suppressed locomotion, which are generally believed to be mediated by the activation of cannabinoid CB1 receptors (CB1Rs). Given recent findings of CB2 and GPR55 receptors in the brain, we examined whether CB2 and GPR55 receptors are also involved in cannabinoid action.
EXPERIMENTAL APPROACH:
We first compared Δ9 -THC-, WIN55212-2-, or XLR11-induced tetrad effects between wild-type (WT) and each genotype of CB1-, CB2-, or GPR55-knockout mice, and then observed the effects of antagonists of these receptors on cannabinoid-induced tetrad effects in WT mice.
KEY RESULTS:
Systemic administration of Δ9 -THC, WIN55212-2, or XLR11 produced dose-dependent tetrad effects in WT mice. Genetic deletion or pharmacological blockade of CB1Rs abolished the tetrad effects produced by all three cannabinoids. Unexpectedly, genetic deletion of CB2Rs also abolished analgesia and catalepsy produced by Δ9 -THC or WIN55212-2, but not by XLR11. Microinjections of Δ9 -THC into the lateral ventricles also produced tetrad effects in WT, but not in CB1-KO, mice. CB2-KO mice displayed a reduction in intra-ventricle Δ9 -THC-induced analgesia and catalepsy. In contrast to CB1Rs and CB2Rs, genetic deletion of GPR55s caused enhanced responses to Δ9 -THC or WIN55212-2. Pharmacological blockade of CB1, CB2, or GPR55 receptors produced alterations similar to those observed in each genotype mouse line.
CONCLUSIONS AND IMPLICATIONS:
These findings suggest that in addition to CB1Rs, both CB2Rs and GPR55s are also involved in some pharmacological effects produced by cannabinoids. CB1/CB2Rs, in contrast to GPR55 receptors, appear to play opposite roles in cannabinoid action.
This article is protected by copyright. All rights reserved.